BioSpace News Archive

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis.

Cullinan Oncology, Inc. announced that its Chief Scientific Officer, Patrick Baeuerle, Ph.D., will deliver a keynote presentation at the William Blair Biotech Focus Conference, being held July 12-13, 2022 in New York.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6, 2022 at 8:30am Eastern Time, the Company will host a webcast and conference call to share new functional data across multiple studies from the clinical development program for SRP-9001 (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy.

MediWound Ltd. announced that it will host an in-person key opinion leader event on EscharEx for analysts and investors on Tuesday, July 12, 2022 at 8:00 am Eastern Time at the St. Regis Hotel in New York, NY.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 7,000 shares of common stock.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 4,000 shares of Akebia’s common stock on June 30, 2022, as inducements material to each such employee entering into employment with Akebia.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 8,000 shares of KalVista common stock on July 1, 2022 as inducements material to each employee entering into employment with KalVista.

Hologic, Inc. announced that the Company plans to release its financial results for the third quarter of fiscal 2022 on Wednesday, July 27, after the market closes.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors.

BD, a leading global medical technology company, announced that Rishi Grover has been named executive vice president and chief integrated supply chain officer for BD, effective July 7, 2022.